Local view for "http://purl.org/linkedpolitics/eu/plenary/2002-10-23-Speech-3-100"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2002-10-23"^^xsd:date2
dcterms:Is Part Of	lp_eu:Vote2
dcterms:Language	"sv"^^xsd:language2
lpv:document identification number	"en.20021023.2.3-100"2
lpv:hasSubsequent	lp_eu:2002-10-23-Speech-3-1012
lpv:speaker	lp:Sacrédeus and Wijkman (PPE-DE )2
lpv:translated text	". We have chosen to support the amendments which make it easier for generic medicinal products, that is to say, cheaper imitations, to be placed on the market more quickly, thus forcing down constantly rising drug expenses. In Sweden, for example, these rose by 10 % each year during the 1990s. The registration procedure for generic medicinal products needs to be simplified, so that it is possible to place generic medicinal products on the market directly upon expiry of the ten-year period following initial authorisation of the reference medicinal product. The manufacture of the generic medicinal products should therefore be able to begin before expiry of the above-mentioned ten-year period. Therefore, we also voted against the amendments which obstruct the placing on the market of generic medicinal products by protecting small changes in the original medicine. We are also determined in our view that the present ban on advertising of medicinal products directly to the public must be maintained. Patients require reliable information from an independent source."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph